Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04280393
Other study ID # FCVHPC-2018-PS-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 10, 2020
Est. completion date November 30, 2021

Study information

Verified date November 2022
Source Hospital Provincial de Castellon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hypothesis of the present study is to demonstrate that ENDOCUFF VISION® increases the detection rate of adenomas thanks to the improved visibility produced by the retraction of the folds and stabilizing the colonoscope. Likewise, the impact of the use of ENDOCUFF VISION® on the average number of adenomas detected per patient (MAPP) as well as serrated adenomas (MASPP), the total time of the endoscopic procedure, cecal intubation and the safety of its use will be estimated.


Description:

The main objective of the colorectal cancer screening program (CRC) is the detection of the greatest number of precursor lesions of neoplasms as well as cancerous lesions established in the general population with an intermediate risk of presenting CRC. Within this program, colonoscopy is considered the diagnostic technique of choice due to its cost-effectiveness balance. However, it remains a technique that is not entirely perfect since the omission of injuries during the procedure constitutes the main reason for the appearance of interval cancers, with a clear correlation between the rate of detection of adenomas and their appearance. The vast majority of CRC arise from precancerous polyps, of which there are two main types: conventional adenomas and serrated polyps. Conventional adenomas are the most frequent polyps being responsible for the majority of CRC through the adenoma-carcinoma sequence. It should be taken into account that about 15-30% of sporadic CRC develops from serrated polyps through the serrated pathway of carcinogenesis, which is different from the traditional adenoma-carcinoma sequence. Endoscopic detection of serrated polyps is difficult due to their indistinguishable edges and flat or sessile morphology. In addition, they tend to be located in the right colon, a place that can be more difficult to reach in colonoscopy and examine completely. Therefore, the ultimate goal of CRC screening colonoscopy is to reduce the appearance of CRC, trying to maximize the detection of polyps and therefore the detection rate of adenomas. For this there are several technical factors of colonoscopy, preparation, imaging and external devices that try to achieve an increase in the rate of detection of adenomas. ENDOCUFF VISION® (Norgine Pharmaceuticals Ltd) is a medical device that is fixed at the distal end of the endoscope, improving its insertion in the intestine thanks to the action it exerts by flattening the folds and stabilizing the device. Its use is related to greater accuracy in the detection of adenomas, since it increases the visibility of the mucosa and thus decreases the number of polyps that may go unnoticed, increasing the detection rate of adenomas between 10 and 16 percentage points, according with published literature . Thus, the hypothesis of the present study is to demonstrate that ENDOCUFF VISION® increases the detection rate of adenomas thanks to the improved visibility produced by the retraction of the folds and stabilizing the colonoscope. Likewise, the impact of the use of ENDOCUFF VISION® on the average number of adenomas detected per patient (MAPP) as well as serrated adenomas (MASPP), the total time of the endoscopic procedure, cecal intubation and the safety of its use will be estimated.


Recruitment information / eligibility

Status Completed
Enrollment 822
Est. completion date November 30, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 50 Years to 70 Years
Eligibility Inclusion Criteria: A) Patients between the ages of 50 and 70 referred for a colonoscopy within the colorectal cancer screening program. B) With the ability to provide informed consent Exclusion Criteria: 1. History of inflammatory bowel disease 2. History or suspected obstruction or intestinal pseudo-obstruction located in the colon 3. History of colon cancer or polyposic syndromes 4. History of colonic stenosis 5. History of severe diverticular segments in some region of the colon 6. Subjects unable to provide informed consent 7. Subjects under treatment with clopidogrel, warfarin, acenocoumarol or other new generation anticoagulants that have not discontinued treatment in accordance with the provisions of these procedures 8. Pregnants females 9. Subjects who are going to undergo a therapeutic or surveillance endoscopy for follow-up of injuries diagnosed in previous procedures 10. Subjects whose baseline status does not allow the completion of the questionnaires necessary for the evaluation of the study objectives. 11. History of previous colonic surgery except for appendectomy 12. Any medical, psychological, psychiatric, geographic or social problem that is important and uncontrolled that may interfere with the patient's participation in the study or that does not allow adequate follow-up and adherence to the protocol and evaluation of the study results.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Colonoscopy procedure with endocuff
Colonoscopy procedure with the use of ENDOCUFF VISION

Locations

Country Name City State
Spain Hospital Provincial de Castellon Castellón De La Plana Castellon

Sponsors (1)

Lead Sponsor Collaborator
Hospital Provincial de Castellon

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary polyps detection rate per patient Rate of polyps detected immediately after the procedure
Primary adenoma detection rate per patient Rate of Adenoma detected immediately after the procedure
Secondary differences in the mean of adenomas detected by patient Assess whether there are differences in the mean of adenomas detected by patient comparing Endocuff Colonoscopy and Standard Colonoscopy. immediately after the procedure
Secondary Serrated adenoma rate detected by patient Rate of serrated adenomas immediately after the procedure
Secondary Cancer lesion detection rate comparing Endocuff Colonoscopy and Standard Colonoscopy. Rate of lessions immediately after the procedure
Secondary Cecal intubation rate and time to reach the cecum Time in minutes of the intubation immediately after the procedure
Secondary Total time of the procedure Total time of the procedure, from the insertion of the colonoscope to its extraction comparing Endocuff Colonoscopy and Standard Colonoscopy. immediately after the procedure
Secondary Colonoscope withdrawal time from cecum Colonoscope withdrawal time from cecum in patients in whom no polyps were detected immediately after the procedure
Secondary Demonstrate the non-inferiority of patient experience when comparing Endocuff Colonoscopy and Standard Colonoscopy Number of Participants With Procedure-Related Adverse Events Intra and post-procedure (evaluated with CTC AE v4) comparing Endocuff Colonoscopy and Standard Colonoscopy. This will be calculated as a Rate of Intra and post-procedure complications. through study completion, an average of 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05536089 - ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
Active, not recruiting NCT04392479 - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. Phase 3
Not yet recruiting NCT05577143 - Blood Screening for Adult Colorectal Cancer
Active, not recruiting NCT05585866 - Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury
Recruiting NCT05573022 - Impact of a Patient Decision Aid Intervention N/A
Completed NCT02931825 - Identification of High Risk People for Colorectal Cancer and Evaluation of a Specific Surveillance System N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Not yet recruiting NCT05791747 - Representations, Beliefs and Attitudes Towards Hypnosis in Patients Followed for Colorectal Cancer
Recruiting NCT05830097 - A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06324409 - ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening N/A
Recruiting NCT04258813 - Onco-primary Care Networking to Support TEAM-based Care N/A
Active, not recruiting NCT05939440 - Interventions to Decrease Financial Toxicity N/A
Completed NCT04548765 - Evaluation of Letters Promoting Colorectal Cancer Testing N/A
Recruiting NCT04189055 - Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. Phase 2
Recruiting NCT04592003 - French Colorectal ESD Cohort in Experts Centers
Withdrawn NCT04345952 - Calm for Cancer Patients Receiving Chemotherapy N/A
Not yet recruiting NCT06231576 - Digital Home-Based Prehabilitation Before Surgery N/A
Recruiting NCT04874883 - Effect of the Use of Symbiotics in Patients With Colon Cancer Phase 4
Completed NCT04074460 - Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study Phase 4
Not yet recruiting NCT06191185 - IMProving Adherence to Colonoscopy Through Teams and Technology N/A